{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:38:06Z","timestamp":1768286286237,"version":"3.49.0"},"reference-count":104,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minister of Science and Higher Education","award":["002\/RID\/2018\/19."],"award-info":[{"award-number":["002\/RID\/2018\/19."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality. Incretins are peptide hormones derived from the gastrointestinal tract, that besides causing enhancement of insulin secretion after oral glucose intake, participate in many other metabolic processes. Antidiabetic drug classes, such as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide receptor agonists, which way of action is based on incretins facility, not only show glucose-lowering properties but also have nephroprotective functions. The aim of this article is to present the latest information about incretin-based therapy and its influence on diabetic kidney disease appearance and progression, point its potential mechanisms of kidney protection and focus on future therapeutic possibilities bound with these two antidiabetic drug classes.<\/jats:p>","DOI":"10.3390\/ijms222212312","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T08:19:20Z","timestamp":1636964360000},"page":"12312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incretins in the Therapy of Diabetic Kidney Disease"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1164-3960","authenticated-orcid":false,"given":"Agnieszka","family":"Przezak","sequence":"first","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika","family":"Bielka","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","article-title":"Incretins, insulin secretion and Type 2 diabetes mellitus","volume":"47","author":"Holst","year":"2004","journal-title":"Diabetologia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/db18-0729","article-title":"Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food","volume":"68","author":"Holt","year":"2019","journal-title":"Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Boer, G.A., and Holst, J.J. (2020). Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches. Biology, 9.","DOI":"10.20944\/preprints202011.0684.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/mi.2017.73","article-title":"Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity","volume":"11","author":"Worthington","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/bph.12689","article-title":"Structure of Class B GPCRs: New horizons for drug discovery","volume":"171","author":"Bortolato","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"Rasmussen","year":"2008","journal-title":"Diabetologia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2005-2220","article-title":"Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses","volume":"91","author":"Little","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JOE-15-0461","article-title":"Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption","volume":"229","author":"Veltman","year":"2016","journal-title":"J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the kidney","volume":"15","author":"Skov","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.2337\/db13-1597","article-title":"Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin\u2019s metabolic action in the presence of insulin resistance","volume":"63","author":"Chai","year":"2014","journal-title":"Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e13073","DOI":"10.14814\/phy2.13073","article-title":"Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men","volume":"5","author":"Asmar","year":"2017","journal-title":"Physiol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1210\/jc.2019-00008","article-title":"Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes","volume":"104","author":"Bergmann","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_31","first-page":"386","article-title":"DPP4 in Diabetes","volume":"6","author":"Wronkowitz","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","article-title":"Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function","volume":"29","author":"Ohnuma","year":"2008","journal-title":"Trends Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.regpep.2004.06.007","article-title":"What do we know about the secretion and degradation of incretin hormones?","volume":"128","author":"Deacon","year":"2005","journal-title":"Regul. Pept."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2174\/1874091X01408010107","article-title":"GLP-1(28-36)amide, a Long Ignored Peptide Revisited","volume":"8","author":"Zhou","year":"2014","journal-title":"Open Biochem. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","article-title":"Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men","volume":"308","author":"Asmar","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_37","first-page":"161","article-title":"Evolution of exenatide as a diabetes therapeutic","volume":"9","author":"Bhavsar","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.2147\/DDDT.S166765","article-title":"The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: Evidence to date","volume":"13","author":"Antza","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., and Brayden, D.J. (2019). Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11020078"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"40Yaribeygi, H., Sathyapalan, T., and Sahebkar, A. (2019). Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci., 234, 116776.","DOI":"10.1016\/j.lfs.2019.116776"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/dom.12671","article-title":"Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic \u03b2-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes","volume":"18","author":"Mari","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2009.45.2.1343904","article-title":"Liraglutide: A new treatment for type 2 diabetes","volume":"45","author":"Vilsboll","year":"2009","journal-title":"Drugs Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_44","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/oby.2007.204","article-title":"Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs","volume":"15","author":"Raun","year":"2007","journal-title":"Obesity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","article-title":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia","volume":"185","author":"Lorenz","year":"2013","journal-title":"Regul. Pept."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/diabetes.50.7.1588","article-title":"Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs","volume":"50","author":"Deacon","year":"2001","journal-title":"Diabetes"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/en.2004-1174","article-title":"Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice","volume":"146","author":"Hughes","year":"2005","journal-title":"Endocrinology"},{"key":"ref_55","first-page":"7","article-title":"Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus","volume":"1307","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications","volume":"124","author":"Nauck","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Duni, A., Liakopoulos, V., Roumeliotis, S., Peschos, D., and Dounousi, E. (2019). Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease: Untangling Ariadne\u2019s Thread. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153711"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/PAP.0000000000000257","article-title":"Diabetic Kidney Disease: Past and Present","volume":"27","author":"Akhtar","year":"2020","journal-title":"Adv. Anat. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Amatruda, M., Gembillo, G., Giuffrida, A.E., Santoro, D., and Conti, G. (2021). The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina, 57.","DOI":"10.3390\/medicina57090868"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"F589","DOI":"10.1152\/ajprenal.00368.2001","article-title":"Diabetic kidney disease: Impact of puberty","volume":"283","author":"Lane","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1573399814666180119141836","article-title":"The Role of Oestrogen Receptor Beta (ER\u03b2) in the Aetiology and Treatment of Type 2 Diabetes Mellitus","volume":"15","author":"Ofosu","year":"2019","journal-title":"Curr. Diabetes Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molmet.2018.06.013","article-title":"The impact of ER\u03b1 action on muscle metabolism and insulin sensitivity\u2014Strong enough for a man, made for a woman","volume":"15","author":"Hevener","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E124","DOI":"10.1152\/ajpendo.00189.2009","article-title":"Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue","volume":"297","author":"Barros","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1073\/pnas.0510391103","article-title":"Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha","volume":"103","author":"Barros","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/labinvest.2014.163","article-title":"Serum amyloid A and inflammation in diabetic kidney disease and podocytes","volume":"95","author":"Anderberg","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","article-title":"Innate immunity in diabetic kidney disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/db16-1585","article-title":"NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy","volume":"66","author":"Jha","year":"2017","journal-title":"Diabetes"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2174\/1389450116666150722141418","article-title":"Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?","volume":"17","author":"Sourris","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"F854","DOI":"10.1152\/ajprenal.00258.2017","article-title":"Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin","volume":"313","author":"Thomson","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/dom.12985","article-title":"Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial","volume":"19","author":"Tonneijck","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_84","first-page":"2042018819865398","article-title":"The incretin pathway as a therapeutic target in diabetic kidney disease: A clinical focus on GLP-1 receptor agonists","volume":"10","author":"Hoogenberg","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"C1238","DOI":"10.1152\/ajpcell.00186.2004","article-title":"Role of dipeptidyl peptidase IV in regulating activity of Na+\/H+ exchanger isoform NHE3 in proximal tubule cells","volume":"287","author":"Girardi","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.kint.2016.06.012","article-title":"Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy","volume":"90","author":"Takashima","year":"2016","journal-title":"Kidney Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metabolism"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08977194.2015.1125349","article-title":"Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice","volume":"33","author":"Bolkent","year":"2015","journal-title":"Growth Factors"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2013020134","article-title":"Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection","volume":"24","author":"Katagiri","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jss.2013.06.042","article-title":"Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat","volume":"185","author":"Yang","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.metabol.2014.06.004","article-title":"Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes","volume":"63","author":"Tremblay","year":"2014","journal-title":"Metabolism"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ajpath.2019.10.008","article-title":"Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation","volume":"190","author":"Kirsch","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1159\/000341454","article-title":"Inhibition of the expression of TGF-\u03b21 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist","volume":"30","author":"Li","year":"2012","journal-title":"Cell Physiol. Biochem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejps.2012.07.003","article-title":"Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats","volume":"47","author":"Akarte","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1210\/en.2010-0068","article-title":"Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor","volume":"151","author":"Tian","year":"2010","journal-title":"Endocrinology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: A systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: Systematic review and meta-analysis","volume":"29","author":"Monami","year":"2012","journal-title":"Adv. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:30:19Z","timestamp":1760167819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":104,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222212312"],"URL":"https:\/\/doi.org\/10.3390\/ijms222212312","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}